FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 431 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 10-Year Data Underscore How ICI Therapy Has Helped to Change the... October 10, 2024 Contraception and cancer – a look behind the headlines March 21, 2023 Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update. May 31, 2019 Load more HOT NEWS Dad Sings “Ave Maria” For His Daughter At Disney World Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan
